本文报告1例低氧诱导因子脯氨酸羟化酶抑制剂(hypoxiainducible factor prolyl hydroxylase inhibitor，HIF-PHI)治疗地中海贫血合并肾性贫血的病例。患者为老年女性，患有β地中海贫血，突变基因CD41-42杂合，因高血压、糖尿病进展为尿毒症，并发肾性贫血。应用促红细胞生成素治疗后，患者贫血不能纠正，长期依赖输血，后改用HIF-PHI罗沙司他治疗有效。
Abstract
We reported a case of hypoxia-inducible factor prolyl hydroxylase inhibitor(HIF-PHI) in the treatment of thalassemia combined with renal anemia.The patient was an elderly female with β-thalassemia, heterozygous for the mutant gene CD41-42, and progressed to uremia due to hypertension and diabetes.After treatment with erythropoietin, the patient's renal anemia could not be corrected, and she relied on blood transfusion for a long time. HIF-PHI Roxadustat is effective in treating this patient.
中图分类号：
R556.7
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] SUGAHARA M, TANAKA T, NANGAKU M. Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease[J]. Kidney Int, 2017, 92(2): 306-312.
[2] CHEN N, HAO C, LIU BC, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis[J]. N Engl J Med, 2019, 381(11): 1011-1022.
[3] CHEN N, HAO C, PENG X, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis[J]. N Engl J Med, 2019, 381(11): 1001-1010.
[4] SCHODEL J, RATCLIFFE PJ. Mechanisms of hypoxia signalling: new implications for nephrology [J]. Nat Rev Nephrol, 2019, 15(10): 641-659.
[5] TAHER AT, WEATHERALL DJ, CAPPELLINI MD. Thalassaemia[J]. Lancet, 2018, 391(10116): 155-167.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(1467 KB)
